# 72. What’s Stopping Us From Curing Rare Diseases?

- **Show:** Freakonomics, M.D.
- **Published:** 10 Feb 2023
- **Source:** https://freakonomics.com
- **Transcript:** https://podcasts.opennash.com/shows/freakonomics-md/72-whats-stopping-us-from-curing-rare-diseases-fddbd9/
- **Provider:** OpenNash Podcasts (machine-generated)

## In brief

Scientific tools for finding and curing rare genetic diseases are advancing faster than the systems built to deliver them. AI can flag undiagnosed patients, and CRISPR gene editing can fix a single faulty DNA letter. But regulation and economics, not biology, now decide which patients actually get treated.

The tension is between capability and incentive. Geneticist Fyodor Urnov says he could design a CRISPR fix in under a year, yet the four-year, roughly $10 million path to the clinic makes it uneconomic for diseases affecting only a few children. Gaurav Singal adds that insurers face a bind: better screening finds more patients needing expensive drugs.

## Key insights

1. **Rare diseases are collectively common** The US defines a rare disease as one affecting fewer than 200,000 people, but there are over 7,000 of them. Together they affect more than 30 million Americans, around 10% of the population.
2. **AI already speeds up stroke diagnosis** Viz.ai runs an FDA-approved algorithm on hospital scanners that flags suspected strokes in head CT scans. Singal says this detects strokes often a dozen minutes or more faster, because incentives line up between payers and hospitals.
3. **CRISPR is a borrowed bacterial defense system** CRISPR is a billions-year-old bacterial defense made of an enzyme that cuts DNA and a guide that tells it where. Doudna and Charpentier showed it can be programmed to fix human genes, which earned the 2020 Chemistry Nobel.
4. **Cost, not biology, blocks ultra-rare cures** Urnov says engineering a CRISPR medicine takes under a year, but reaching the clinic takes about four years and $8 to $10 million. No company can recoup that for a disease affecting two children.
5. **Earlier screening could strain payers** Singal notes that screening more people for rare conditions identifies more patients who need expensive treatment, putting insurers in a bind. Unlike stroke detection, the financial incentives are not yet aligned.

## Questions this episode answers

### What exactly is CRISPR and how does it edit DNA?

Urnov describes CRISPR as a bacterial defense system with two parts: an enzyme that works like scissors and a guide molecule that tells it where in the DNA to cut. Scientists can program the guide to match a broken human gene and fix it.

### Why can't scientists just make a CRISPR cure for every child with a rare genetic disease?

Urnov says designing the medicine is fast, but testing it for safety and reaching the clinic takes about four years and $8 to $10 million. For a disease affecting only a couple of children, no company has a financial reason to do it.

### How common are rare diseases?

Each one affects fewer than 200,000 Americans, but there are more than 7,000 of them. Together they affect over 30 million people, roughly 10% of the US population.

### How can AI help people with rare diseases?

Singal says AI can quietly scan existing data like EKGs, scans and lab results to spot patterns suggesting a rare condition. It then flags the patient or doctor so they can get confirmatory testing, shortening years-long diagnostic odysseys.

### Has CRISPR actually been used to treat patients?

Yes. According to Urnov, it has been used for genetic diseases of the blood, liver, eye and immune system, and a sickle cell therapy was the first CRISPR-based treatment up for FDA approval. Organs like the lungs, brain and kidneys are harder to reach.

## Facts

- **Bapu Jena** [0:02:08]: "The National Institutes of Health invest more than $40 billion in biomedical research each year."
- **Bapu Jena** [0:02:42]: "And the private sector in the U.S. spends more than twice that."
- **Gaurav Singal** [0:07:02]: "One example is a company called VizAI that has an FDA-approved algorithm for detecting stroke in the emergency room."
- **Gaurav Singal** [0:07:26]: "The result of this has been faster detection of strokes, often by a dozen minutes or more,"
- **Bapu Jena** [0:09:08]: "The U.S. government defines rare diseases as those that affect fewer than 200 ,000 people in the country."
- **Bapu Jena** [0:09:08]: "Taken altogether, more than 30 million people in the United States have been diagnosed with a rare disease."
- **Bapu Jena** [0:11:46]: "The first complete sequence of the human genome was obtained two decades ago. It took about a decade and $3 billion."
- **Bapu Jena** [0:12:11]: "And 24 hours later, you can get a link to your complete genetic sequence."
- **Bapu Jena** [0:17:35]: "In you and I, it carries 20 ,000 such genetic instructions, which we call genes."
- **Bapu Jena** [0:18:09]: "like a mutation that occurred around 5 ,000 years ago that allowed humans to digest lactose for the first time."
- **Bapu Jena** [0:18:56]: "Around 100 ,000 Americans suffer from it, so we classify it as a rare disease,"
- **Bapu Jena** [0:19:34]: "All of these bad outcomes are the result of just one letter out of 6 billion in the genome being flipped."
- **Bapu Jena** [0:20:10]: "even with the best health care, our fellow Americans with sickle cell disease, their lifespan is around the mid-40s."
- **Bapu Jena** [0:20:10]: "Until now, the only way to cure sickle cell disease was with a bone marrow transplant."
- **Bapu Jena** [0:21:54]: "That discovery was made by the biochemist Jennifer Doudna, who, together with Emmanuel Charpentier, won the 2020 Nobel Prize in Chemistry."
- **Bapu Jena** [0:21:54]: "It's a microbial defense mechanism. It consists of just two molecules, an enzyme that acts as a pair of DNA scissors"
- **Bapu Jena** [0:24:15]: "Geneticists made use of that function to develop a cure for sickle cell disease, which is currently the first CRISPR-based therapeutic up for approval by the FDA."
- **Bapu Jena** [0:24:50]: "So far, CRISPR has been used to treat genetic diseases of the bloodstream, liver, eye, and immune system"
- **Bapu Jena** [0:29:30]: "A really profound and poignant example is the disease that killed woody guthrie which is huntington's disease"
- **Gaurav Singal** [0:13:58]: "The payer is caught in a bind here because if we screen more for rare conditions, we identify more patients who will need to have expensive treatments."

## Transcript

**[0:00:00] Speaker 5:** Your business relies on technology every day, but how confident are you in the security behind it? As your business evolves, so do the cybersecurity challenges that come with it. That's why BPM's Cybersecurity Risk Assessments help leaders better understand cyber risk, identify vulnerabilities, and develop a practical roadmap for stronger security. Build confidence in your cybersecurity strategy. Learn more at bpm.com slash cyber.

**[0:00:28] Speaker 3:** Believe in holiday magic? Then follow the twinkling lights to holidays in Yauntville, Napa Valley's most festive town. Discover more than 50 merry experiences, from holiday craft classes and wine tastings, to cooking demonstrations and charming store open houses. Add sparkling holiday lights, luxurious resorts, and incredible cuisine, and you found your own holiday wonderland. Make this season extraordinary in Yauntville, from Thanksgiving weekend through New Year's. Visit yauntville.com and make your own holiday magic.

**[0:01:01] Bapu Jena:** I got an email from a parent of a child who is going progressively blind. This parent writes to me and says, look, my child is an amazing student and she's doing so well, but she's going to lose vision. It's going to happen. We don't know when. Can you stop it? Every day, Dr. Theodor Ernoff's inbox is flooded with emails like that one. and they put him in a difficult position because he has the technology to stop it.

**[0:01:31] Bapu Jena:** Theodore is a professor at UC Berkeley and a leading researcher in the field of genomic therapies. He develops medications that change people's DNA to cure genetic diseases like the one described in that email. We're not just sitting here hand-wringing at the fault that's in our stars. We can actually fly to the stars and touch them and manipulate them. But having the ability to do something and actually doing it are two very different things. Medicine has always suffered from a problem called the no-do gap.

**[0:02:08] Bapu Jena:** It's the difference between what we actually do for our patients and what we could do, given all that we know. Breakthroughs in biomedicine are allowing doctors to do things they could never do before. But sometimes these advances don't fit into our financial or regulatory systems. That means it can take a long time for patients to actually benefit, time that many of them don't have to spare. The National Institutes of Health invest more than $40 billion in biomedical research each year.

**[0:02:42] Bapu Jena:** And the private sector in the U.S. spends more than twice that. Clearly, we value these discoveries. Why is it so hard to use them? From the Freakonomics Radio Network, this is Freakonomics MD. I'm Bapu Jena. Today on the show, we'll talk about the promise of life-saving genetic treatments. But first, how can we find the people who might benefit from them?

**[0:03:09] Gaurav Singal:** What if artificial intelligence could examine the fingerprints, the breadcrumbs that patients leave throughout the healthcare system?

**[0:03:16] Bapu Jena:** And Fyodor Ernoff will tell us how editing the human genome can cure disease, and why his answers to those desperate emails aren't so straightforward. Our ability to engineer these CRISPR medicines has far outpaced how these medicines are actually built, tested, and put into human beings.

**[0:03:49] Gaurav Singal:** I'm Garv Singel. I'm a physician and computer scientist, studied artificial intelligence and robotics, and ultimately became a doctor to see patients.

**[0:03:58] Bapu Jena:** When you say you have a background in robotics, does that just mean you used to play with Legos?

**[0:04:02] Gaurav Singal:** Yeah, no, actually, I helped build a Lego-based team of autonomous soccer-playing robots as an undergraduate. And they were in the World Cup recently? They were in the RoboCup, actually. We played at Carnegie Mellon and got destroyed by robots that had seven wheels. We had two wheels and, you know, lost. Are you joking or is this... I'm 100 % serious.

**[0:04:23] Bapu Jena:** When he's not playing with Legos, my friend Gaurav spends his time using computer science to solve healthcare problems. Most recently, he was the chief data officer of a company called Foundation Medicine, which develops tests that diagnose cancer patients with specific genetic mutations. Now he sees patients at Brigham and Women's Hospital in Boston and advises other companies that are using big data and artificial intelligence to solve problems in medicine. Artificial intelligence in a doctor's office may sound as science fiction as, say, soccer-playing robots, but the fact is that artificial intelligence already permeates our lives.

**[0:05:10] Gaurav Singal:** credit card companies have been using artificial intelligence to help map risk scores as part of your credit evaluation spotify uses artificial intelligence to make personalized recommendations things like google photos have the ability to match photos of my children all the way from when they were born till now when they're nine and seven that's incredible the metric for a long time has been, can computers do things as well as humans? But you see places like this task of matching infant pictures to childhood pictures where computers outperform humans.

**[0:05:43] Gaurav Singal:** And once you cross that threshold, you get to a real opportunity where computers could complement humans. So when we get to medicine, I think this becomes particularly relevant. What are computers and artificial intelligence good at? Two things at least. Number one, pattern matching. Number two, doing things very quickly. So where those two things are important, there may be a real role for computers and artificial intelligence. One example where that's the case is diagnosing strokes. When a patient has a stroke, part of the blood flow to their brain has been blocked.

**[0:06:13] Gaurav Singal:** And every minute that goes by, more and more neurons die. If you wait too long, that brain tissue has already died. And in fact, opening up the blood vessel

**[0:06:21] Bapu Jena:** no longer has any benefit. When a patient shows up at the emergency room with a suspected stroke, they need to get treatment fast. But first, to confirm what kind of stroke they had, those patients usually get a CT scan, which has to be read by a radiologist.

**[0:06:38] Gaurav Singal:** That's a very busy environment. And maybe the case that that CT scan of the head, very important, very time-sensitive, is in a queue of equally important and equally urgent scans that that radiologist has to read. So it may take five minutes, 10 minutes, 20 minutes for that radiologist to review it to see if it has a stroke, only after which can that patient be evaluated and hopefully treated if it's in the time window for treatment.

**[0:07:02] Gaurav Singal:** One place that artificial intelligence has already had an impact is analyzing scans of these head CTs in the emergency room faster than a radiologist ever could. One example is a company called VizAI that has an FDA-approved algorithm for detecting stroke in the emergency room. that lives on the scanner of hospitals all over the country.

**[0:07:21] Bapu Jena:** I should note that Viz.ai is one of the companies that Gaurav has consulted with.

**[0:07:26] Gaurav Singal:** Every time a scan is taken of someone's head, that algorithm runs on that scan and determines if it believes there's a stroke there. If a stroke is detected by the algorithm, a radiologist immediately reviews it, determines if that patient has indeed had a stroke, and rushes the next steps for intervention. The result of this has been faster detection of strokes, often by a dozen minutes or more,

**[0:07:47] Bapu Jena:** Stroke is really, really common. Are there examples where this technology is being deployed in areas where the diseases are much less common, what we might call rare diseases?

**[0:07:59] Gaurav Singal:** I think rare diseases are the next frontier for computational diagnostics. They're not diseases that most providers see every day by definition, and as a result, believed to be highly underdiagnosed. Meaning, for some of these conditions, the subset of people who know that they have the condition is a small minority of the people who actually have the condition. A common expression that we probably both heard in training is when you hear hoofbeats, think horses, not zebras, that the rare diseases one thinks about later.

**[0:08:29] Gaurav Singal:** On the flip side of that, if you're a patient with a rare disease, that can be a very frustrating experience. It can mean going from doctor to doctor, from proposed diagnosis to proposed diagnosis, a litany of tests and evaluations and treatments, all without any benefit while you're on what is often termed a diagnostic odyssey. That can take months. It can take years. It can take lots of expense and heartache and frustration. if there were a way to make that diagnosis earlier, that could be tremendously beneficial to the patient, to the health system, avoiding all this unnecessary work and getting on the right treatment sooner.

**[0:09:08] Bapu Jena:** The U.S. government defines rare diseases as those that affect fewer than 200 ,000 people in the country. Some affect only a handful of people. But the word rare can be misleading when talking about rare diseases because there are more than 7 ,000 of them. Taken altogether, more than 30 million people in the United States have been diagnosed with a rare disease. That's around 10 % of the population. So improving how we find and care for those patients could have a really big impact.

**[0:09:41] Gaurav Singal:** What if artificial intelligence could examine the fingerprints, the breadcrumbs that patients leave throughout the healthcare system as part of their routine care through the radiology imaging they've gotten, The EKGs that have been done, the lab work they've had done, what if it were possible for AI to interpret that in the background passively without anybody even needing to think about the rare disease and have proactively brought it up and alert the patient or the physician that, hey, this is something that you might want to keep an eye out for.

**[0:10:10] Gaurav Singal:** I noticed this pattern. That feels like an incredibly powerful area. And I believe there's real examples where that's now possible. One example might be looking at an EKG. there's a lot more signal in EKG than just have you had a heart attack or not. It's incredibly rich analysis of the electrical conduction of the heart. And in fact, there are now a number of different research scientists across the country that have demonstrated that if you give a computer sufficient training in analyzing an EKG, using artificial intelligence, a computer can predict which subset of patients is more likely to have one of these rare conditions.

**[0:10:49] Bapu Jena:** Don't you worry about false positives in this sort of scenario?

**[0:10:52] Gaurav Singal:** That's a great point. Artificial intelligence isn't perfect, like any screening test. It flags people who may have the condition, and then they can go get the confirmatory testing. The problem is today, we're not flagging enough people who are at risk, and as a result, the majority of people with some of these conditions don't know they have it.

**[0:11:10] Bapu Jena:** Theodore Urnov, the geneticist we heard from earlier, is all too familiar with the diagnostic odyssey that Gorv described. It's heartbreaking. But the good news is a key technology advance has happened literally in the past five years that I think is an enormous call to action for pretty much the entirety of the biomedical community. Theodore isn't talking about artificial intelligence. He's talking about an advance in the next step on the path to diagnosis. The one that would come after a patient is flagged by AI as being at risk for a rare disease.

**[0:11:46] Bapu Jena:** Genetic testing. The first complete sequence of the human genome was obtained two decades ago. It took about a decade and $3 billion. Today, there's a room on the UC Berkeley campus and on the UCSF campus across the way or at Stanford or a large number of places where you can walk into the door and a technician will take one of those little swabs, you know, the ones you use for COVID tests. And swirl them in your mouth or your nose.

**[0:12:11] Bapu Jena:** And 24 hours later, you can get a link to your complete genetic sequence. If you asked me when I was a graduate student, in the mid-90s at Brown, do you think we'll ever get to a time where we could do that in a day? I'd go, oh, come on. We'd more likely move faster than the speed of light. And yet here we are. This isn't some hypothetical something that will exist in 2033. This exists in January 2023.

**[0:12:35] Bapu Jena:** So the technologies to read DNA at an incredible rate are here and they got so much cheaper. And so these folks who described to me the harrowing odyssey of like, what's wrong with my child? Should not suffer. We as a society, we as a species, owe it to folks in such predicaments to develop and deploy a scalable

**[0:12:58] Gaurav Singal:** solution of rapid genetic diagnosis. AI could serve a lot of other functions in healthcare, including helping design new treatments, helping predict which treatment is better for which patient. But the idea of screening for rare diseases or diagnosing undiagnosed conditions,

**[0:13:15] Bapu Jena:** these feel absolutely here and now. And as Gaurav said earlier, artificial intelligence is already being used in emergency rooms to instantaneously screen for a more common disease,

**[0:13:28] Gaurav Singal:** stroke. You're improving patients' lives by decreasing morbidity from stroke in a way that It saves payers money and increases the number of procedures that are done in a fee-for-service environment. And so you have incentive alignment between payers and healthcare systems to do what's in the best interest of patients. Implementation is not trivial. You have to deploy software algorithms, workflow tools behind the firewall of hundreds and thousands of health systems. You have to get providers to use the tools.

**[0:13:58] Gaurav Singal:** You have to get them to make decisions based on them. There are a lot of hurdles that have to be overcome. And yet, when incentives are aligned, that can happen. The question is what will be required for the example of detecting rare cardiovascular condition from EKGs to become real? The payer is caught in a bind here because if we screen more for rare conditions, we identify more patients who will need to have expensive treatments. On the other hand, you have an entire industry that's developing novel medicines for these patients who can't get the medicine today because they don't even know they have the condition that's being treated.

**[0:14:33] Bapu Jena:** Theodore Ernoff is among the scientists developing those novel medicines. But his work comes with its own set of economic challenges. We owe it to the patients and the families to aggressively build a new framework. That's after the break. I'm Bob Bougena, and this is Freakonomics, M.D..

**[0:15:19] Speaker 5:** stronger security. Build confidence in your cybersecurity strategy. Learn more at bpm.com

**[0:15:27] Speaker 3:** slash cyber. Believe in holiday magic? Then follow the twinkling lights to holidays in Yontville, Napa Valley's most festive town. Discover more than 50 merry experiences from holiday craft classes and wine tastings to cooking demonstrations and charming store open houses. Add sparkling holiday lights, luxurious resorts, and incredible cuisine, and you found your own holiday wonderland. Make this season extraordinary in Yauntville from Thanksgiving weekend through New Year's. Visit yauntville.com and make your own holiday magic. Fidelity Active ETFs have the

**[0:16:00] Speaker 4:** flexibility to shift and transform as markets do the same. So instead of just riding an index, they can seek to outperform it by adapting to market conditions and pursuing new opportunities as they emerge. And while you get the potential outperformance of an actively managed fund, You can still buy and sell it on your terms, just like any other ETF. Markets can change in real time. Make sure your ETF can, too. Learn more at fidelity.com slash active ETFs.

**[0:16:29] Speaker 4:** Before investing in any exchange-traded fund, you should consider its investment objectives, risks, charges, and expenses. Contact Fidelity for a prospectus, an offering circular, or if available, a summary prospectus containing this information. Read it carefully. While active ETFs offer the potential to outperform an index, these products may more significantly trail an index as compared with passive ETFs. ETFs are subject to market fluctuation and the risks of their underlying investments. ETFs are subject to management fees and other expenses.

**[0:16:54] Speaker 4:** Fidelity Broker Services, LLC, member NYSE, SIPC.

**[0:17:00] Bapu Jena:** What is DNA? Explain it in a way that someone who doesn't have a medical background would understand. Asking a geneticist what's DNA is like asking an astronomer what's a star. You know, it's a ball of flight. Before the break, I mentioned that Dr. Fyodor Ernoff is developing treatments for genetic diseases. But first, let's take a step back. What is a genetic disease? And seriously, what's DNA? Like, what is it, really? It's a molecule, so it consists of atoms, just like everything else.

**[0:17:35] Bapu Jena:** And it has two remarkable properties that pretty much no other molecule has. It can carry in it genetic information, just like a piece of paper can carry a sentence. DNA can carry genetic sentences. In you and I, it carries 20 ,000 such genetic instructions, which we call genes. But the other property of DNA, which inspired me to devote my life to it, is that it's conceptually and molecularly straightforward to make a copy of it. But that copying process isn't foolproof.

**[0:18:09] Bapu Jena:** As DNA reproduces itself again and again, sometimes there are little typos or mutations in the genetic instructions it holds. That's the basis of a process which we call evolution that gave us this wonderful constellation of bacteria, animals, plants, you and I. If DNA never changed, you and I would still be little microbes floating around in the primordial soup. So this intrinsic ability of DNA to change is the basis of life, paradoxically. Some of these changes have beneficial outcomes, like a mutation that occurred around 5 ,000 years ago that allowed humans to digest lactose for the first time.

**[0:18:56] Bapu Jena:** I'm happy I adhered to that one. But sometimes, the outcomes of a typo in genetic instructions can change our lives for the worse. Those are what we call genetic diseases. One of the more common ones you may have heard of is sickle cell disease. Around 100 ,000 Americans suffer from it, so we classify it as a rare disease, even though it's the most common inherited blood disorder in the country and affects millions of people worldwide. People who inherit sickle cell disease can't form normal red blood cells that carry oxygen.

**[0:19:34] Bapu Jena:** Instead, they produce red blood cells that are rigid and sickle-shaped, like a crescent. That deformity causes extreme pain episodes that put sickle cell patients in the hospital on a regular basis. It also delays normal development in children, damages joints, nerves, and organs, and often causes strokes. All of these bad outcomes are the result of just one letter out of 6 billion in the genome being flipped. One tiny typo spreads its devastating effects through the entire body.

**[0:20:10] Bapu Jena:** And even with the best health care, our fellow Americans with sickle cell disease, their lifespan is around the mid-40s. So it takes away decades from your life. Until now, the only way to cure sickle cell disease was with a bone marrow transplant. But the procedure is not for everyone. It can be difficult to find a well-matched donor, and bone marrow transplants are really hard on the body, especially as patients get older. What if instead of replacing the patient's faulty bone marrow, doctors could actually fix the typo in the patient's own bone marrow.

**[0:20:49] Bapu Jena:** That would be a much safer procedure and eliminate the need for a well-matched donor, meaning anyone with the disease could potentially be cured. Thanks to a revolutionary gene-editing technology called CRISPR, scientists like Theodore are now doing exactly that. The first thing to note about CRISPR is it's one of those acronyms where what the acronym stands for is not useful to know because it doesn't tell you anything about what it does. And there are great examples to the contrary.

**[0:21:25] Bapu Jena:** Let's say SCUBA, right? Or self-contained underwater breathing apparatus. If you know what the acronym stands for, you're like, aha. Ah, but CRISPR stands for clustered regularly interspaced short palindromic repeats, and your audience is welcome to forget that immediately. Or say it a hundred times, it'll help you go to sleep. Or become the least popular person at a social gathering. Hey, I know what CRISPR stands for. So I'm sitting in a recording studio at the School of Journalism of the University of California, Berkeley, where I'm a professor.

**[0:21:54] Bapu Jena:** And probably the single biggest discovery in biomedicine of the past quarter century was made here on the Berkeley campus. That discovery was made by the biochemist Jennifer Doudna, who, together with Emmanuel Charpentier, won the 2020 Nobel Prize in Chemistry. To be clear, Jennifer and Emmanuel didn't create CRISPR. CRISPR is not a fancy new lab machine. It's a microbial defense mechanism. It consists of just two molecules, an enzyme that acts as a pair of DNA scissors and a special piece of genetic material that tells the enzyme where in the DNA to cut.

**[0:22:34] Bapu Jena:** And it's billions of years old. Early in the history of life, bacteria evolved CRISPR to fight off parasites that could attack and kill them. It's basically a little molecular machine that carries in it a memory of a previous attack by a genetic invader, a snippet of the offender's genetic material, like a law enforcement officer with a most wanted poster with a picture of somebody suspected of a crime. And it literally matches every piece of DNA it sees.

**[0:23:05] Bapu Jena:** Do you have a match to this 20-letter word that I'm carrying inside me? If yes, I'll cut you and destroy you. If not, have a nice day. Jennifer and Emmanuel's big discovery was not that CRISPR exists. What they discovered was something that CRISPR can do. So it turns out that you can put CRISPR inside human cells, which seems insane. This thing comes from bacteria, which are billions of years apart from us evolutionarily. You can take CRISPR, you can give it a 20-letter match to a human gene that's broken, and it'll fix it.

**[0:23:38] Bapu Jena:** We don't understand why it's been so successful in this incredible new environment, but we're grateful to Mother Nature and, of course, to Jennifer and Emmanuel for having the insight that you can program. This is the key word. CRISPR can be programmed. Not only have scientists wielded CRISPR's innate destructive function to eliminate toxic genes, but they've also come up with ways to make CRISPR serve a constructive function, that is, to precisely alter just one letter in the DNA to repair a gene rather than getting rid of it altogether.

**[0:24:15] Bapu Jena:** Geneticists made use of that function to develop a cure for sickle cell disease, which is currently the first CRISPR-based therapeutic up for approval by the FDA. This is a great example of the ways in which we humans have borrowed from Mother Nature and then elaborated on her inventions. And we wouldn't be talking about this if this hasn't been used on people. CRISPR isn't the first approach to gene therapy. There are several approved medications that use modified viruses to deliver disease-treating genetic material into a patient's cells.

**[0:24:50] Bapu Jena:** But CRISPR cures are the first to edit the genome itself So far, CRISPR has been used to treat genetic diseases of the bloodstream, liver, eye, and immune system For others, like those affecting the lungs, brain, and kidneys Scientists haven't yet figured out how to get CRISPR into enough of the organ to actually heal it So, to be clear, CRISPR is still far from a cure-all But as new techniques and technologies to deliver CRISPR are developed, more and more organs will come online.

**[0:25:26] Bapu Jena:** Theodore expects the lungs to be next. Having the power to cure genetic diseases by editing the human genome is a dream come true for geneticists. But when it comes to using that power to help people, the story gets more complicated. Many a time when parents of children with severe genetic disease send me a note saying, Dr. Ernov, is there anything you can do? If they are willing to share what the mutation is, I can load it into some software on my computer, which is available to all.

**[0:25:59] Bapu Jena:** I want to be clear on some proprietary UC Berkeley software. And you can basically engineer, if you know what you're doing, a CRISPR to fix that mutation. For many diseases, that engineered CRISPR on my computer screen can become a vial. with that CRISPR that we can pretty quickly test for whether it can repair the defect safely and effectively. Start to finish, if you know what you're doing, it'll take well under a year. So do I write back to the parents and say, hi, guess what?

**[0:26:27] Bapu Jena:** No. And here's why. Engineering the medicine is the first step of probably a four-year process to protect patients from faulty medicines. I want to really emphasize, I'm not sitting here and saying, get rid of the loss to protect patients from faulty medicines. But going through that four-year process just to get to the clinic takes anywhere between eight to $10 million for one disease. If the disease is relatively prevalent, like sickle cell disease, and then if they charge what is currently being charged for these types of medicines, which is one to two to $3 million a patient, I can see why a company would invest years and millions to build a medicine.

**[0:27:07] Bapu Jena:** Okay, now I get this email from somebody and they have two children and both children have this change and it's unclear that anybody else on planet Earth has that genetic change. So who exactly is going to spend four years and $10 million building a medicine that's going to be used to treat two kids? Many of these diseases are individually so rare that they do not form a viable commercial proposition under the current system. We need to face the remarkable reality that our ability to engineer these CRISPR medicines has far outpaced how these medicines are actually built, tested, and put into human beings.

**[0:27:45] Bapu Jena:** We have never had a technology like CRISPR. We owe it to the patients and the families to aggressively build a new framework to provide these medicines to these individuals. It scares me because it's one thing to say to somebody that we don't have a treatment because the biology doesn't exist to provide that treatment. It's another thing to say that we don't have a treatment because there's not sufficient commercial incentive to develop that treatment, to evaluate it, to test it, to market it, or that we have a set of regulatory policies that aren't adept enough to recognize that there are some patients with some diseases who literally months matter in terms of getting access to care.

**[0:28:31] Bapu Jena:** We want to get medicines to people faster, but we want to make sure that we do so in a way that's safe. And the FDA is really tasked with managing that speed safety trade-off. But of course, that trade-off should change when the parameters change, right? So if you have a new technology that will allow for personalized intervention in people with life-threatening diseases for which early treatment really does matter, we should be able to create a regulatory pathway that would allow for that.

**[0:29:00] Bapu Jena:** And then there's the other bucket of, all right, well, how do we pay for that? that commercialization issue is equally important. I cannot improve on what you just say. I'll just add one point. Many genetic diseases are diagnosed in human beings at a stage where current technology, and I emphasize current because our field is moving very fast, current technology is essentially powerless. By the time we're looking at that human being in a clinic, it's too late.

**[0:29:30] Bapu Jena:** A really profound and poignant example is the disease that killed woody guthrie which is huntington's disease it's a broken gene it's actually a toxic gene which is basically killing the brain and by the time people develop symptoms parts of their brain are just gone and we don't have a technology that can bring it back remember the email from the very beginning of the episode that theodore received from the parent of a girl going progressively blind? We don't know if we'll be able to turn back time and bring back vision to 100%.

**[0:30:06] Bapu Jena:** But at the very least, if we can diagnose early enough, if we can intervene at the genetic level before it gets worse, I can tell you that the patient community, the vast worldwide community of folks with genetic disease, will applaud. This brings us back to artificial intelligence and its role in catching these rare genetic diseases as early as possible. Here's Gaurav Singel again.

**[0:30:29] Gaurav Singal:** Now that they're effective treatments, it feels more important than ever that we use techniques like this to make sure that people who have this condition know they have it so they can get treated.

**[0:30:38] Bapu Jena:** And in Theodore's eyes, this is a two-way street. I think we as a community owe it to the folks out there whose genetic changes we're identifying as potentially dangerous or disease-driving to make sure that our ability to address those changes actionably in the clinic It catches up to how quickly we can identify them. Suppose that we can solve the economic puzzle. What's your big picture ideal vision? A world where genetic disease is diagnosed early in a way that's so affordable that health insurance just covers it.

**[0:31:14] Bapu Jena:** And then in cases where that's appropriate, the CRISPR medicine is manufactured and administered to that individual in a way that is scalable, affordable, and does not involve years and millions. Really having, I don't know what we're going to call them, CRISPR clinics? Today, you know, I'm wearing glasses. It's a way to correct my myopia. Do I see a future where CRISPR is deployed to repair genetic defects in a way that's relatively commonplace? I do. That's a world I want to live in.

**[0:31:49] Bapu Jena:** So how can we solve the economic puzzle? How can we make developing cures for rare genetic diseases profitable and accessing those cures affordable?

**[0:32:00] Speaker 5:** Financing ends up being a tremendous roadblock. But with the right kind of financing, it actually ends up accelerating our ability to treat these patients.

**[0:32:10] Bapu Jena:** And what's it like to receive a CRISPR cure? It all amounted to a small syringe of DNA that took about 30 seconds to infuse. and my life changed completely. That's coming up next week on Freakonomics MD. In the meantime, let us know what you thought about the show. I'm at bapu at freakonomics.com. That's B-A -P-U at freakonomics.com. That's it for today. I'd like to thank my guests this week, Dr. Gaurav Singhal and Dr.

**[0:32:42] Bapu Jena:** Fyodor Ernoff. And thanks to you, of course, for listening.

**[0:32:47] Speaker 3:** Freakonomics MD is part of the Freakonomics Radio Network, which also includes Freakonomics Radio, No Stupid Questions, and People I Mostly Admire. All our shows are produced by Stitcher and Renbud Radio. You can find us on Twitter at DrBapuPod. And now you can find our episodes on YouTube, too, by going to YouTube.com slash at Freakonomics. That's the at sign followed by Freakonomics. If you know someone who doesn't listen to podcasts, but spends a lot of time on YouTube, let them know.

**[0:33:22] Speaker 3:** This episode was produced by Julie Canfer and Lyric Baudich. It was mixed by Eleanor Osborne. Our executive team is Neil Carruth, Gabriel Roth, and Stephen Dubner. Original music composed by Luis Guerra. As always, thanks for listening.

**[0:33:45] Bapu Jena:** For the last 22 years, every time I talk to my biology colleagues, I'm always happy that I did a PhD in economics. But when I'm talking to you, I'm thinking to myself, doggone it, why didn't I do something different 22 years ago? But wait, you are an MD, right? I'm an MD and a PhD in economics. Yeah, both. Wow. That's two lives in one. Yeah, exactly. Yeah. I don't know if it's a good thing or a bad thing.

**[0:34:17] Speaker 3:** The Freakonomics Radio Network. The hidden side of everything. Stitcher.

**[0:34:29] Bapu Jena:** Your business relies on technology every day. But how confident are you in the security behind it?

**[0:34:35] Speaker 5:** As your business evolves, so do the cybersecurity challenges that come with it. That's why BPM's Cybersecurity Risk Assessments help leaders better understand cyber risk, identify vulnerabilities, and develop a practical roadmap for stronger security. Build confidence in your cybersecurity strategy. Learn more at bpm.com slash cyber.

**[0:34:58] Speaker 3:** Believe in holiday magic? Then follow the twinkling lights to Holidays in Yontville, Napa Valley's most festive town. Discover more than 50 merry experiences, from holiday craft classes and wine tastings to cooking demonstrations and charming store open houses. Add sparkling holiday lights, luxurious resorts, and incredible cuisine, and you found your own holiday wonderland. Make this season extraordinary in Yauntville, from Thanksgiving weekend through New Year's. Visit yauntville.com and make your own holiday magic.
